Metabolic changes during 5 months treatment with olanzapine or risperidone: Preliminary results from randomized trial

被引：0
|
作者：
Smith, RC
Lindenmayer, JP
Buga, A
Matute, M
Vaidhyanathaswamy, S
Warner-Cohen, J
机构：
[1] NYU, Sch Med, Hewlett, NY USA
[2] Manhattan Psychiat Ctr, Wards Isl, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2004年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：S226 / S226
页数：1
相关论文
共 50 条
  • [21] The metabolic and clinical effects of olanzapine and quetiapine: Preliminary findings from a randomized single-blind trial in patients with schizophrenia
    Ozguven, HD
    Oner, O
    Baskak, B
    Oner, P
    Atbasoglu, EC
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 190 - 191
  • [22] Risperidone versus haloperidol treatment in dual diagnosis inpatients: preliminary results from a 6 week, randomized controlled, open label pilot trial
    Gimelfarb, Y.
    Natan, Z.
    Mashiah, M.
    Dlayahu, Y.
    EUROPEAN PSYCHIATRY, 2007, 22 : S194 - S194
  • [23] Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study
    Philip D. Harvey
    Michael F. Green
    Susan R. McGurk
    Herbert Y. Meltzer
    Psychopharmacology, 2003, 169 : 404 - 411
  • [24] Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study
    Harvey, PD
    Green, MF
    McGurk, SR
    Meltzer, HY
    PSYCHOPHARMACOLOGY, 2003, 169 (3-4) : 404 - 411
  • [25] Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone:: results of an observational study (EFESO study)
    Sacristán, JA
    Gómez, JC
    Ferre, F
    Gascón, J
    Bravo, AP
    Olivares, JM
    ACTAS ESPANOLAS DE PSIQUIATRIA, 2001, 29 (01): : 25 - 32
  • [26] A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia
    Mortimer, A
    Martin, S
    Lôo, H
    Peuskens, J
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (02) : 63 - 69
  • [27] A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone
    Perez-Iglesias, Rocio
    Crespo-Facorro, Benedicto
    Amado, Jose Antonio
    Garcia-Unzueta, Maria Teresa
    Ramirez-Bonilla, Maria Luz
    Gonzalez-Blanch, Cesar
    Martinez-Garcia, Obdulia
    Vazquez-Barquero, Jose Luis
    JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (11) : 1733 - 1740
  • [28] Metabolic comparisons from a 6-month randomized trial of olanzapine and quetiapine in schizophrenia
    Bushe, Chris
    Poole-Hoffmann, Vicki
    Lipkovich, Ilya
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 80S - 80S
  • [29] Randomized assessment of strategies for switching patients with sub-optimal treatment outcomes from olanzapine to risperidone
    Ganguli, R
    Berry, S
    Gharabawi, G
    Lonchena, C
    Mahmoud, R
    Brar, J
    Pandina, G
    BIOLOGICAL PSYCHIATRY, 2003, 53 (08) : 123S - 123S
  • [30] Quality of life in the treatment of schizophrenia - A randomized, open-label comparison trial of amisulpride, olanzapine, quetiapine, risperidone and zotepine
    Lambert, M
    Moritz, S
    Karow, A
    Krausz, M
    Naber, D
    SCHIZOPHRENIA RESEARCH, 2002, 53 (03) : 176 - 176
12345